{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:25:34Z","timestamp":1791912334245,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Seasonal influenza poses a substantial clinical and economic burden in the United States and vulnerable populations, including the elderly and those with comorbidities, are at elevated risk for influenza-related medical complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using the IQVIA PharMetrics\u00ae Plus claims database in two stages. In Stage 1, we identified patients with evidence of medically-attended influenza during influenza seasons from October 1, 2014 to May 31, 2018 (latest available data for Stage 1) and used a multivariable logistic regression model to identify patient characteristics that predicted 30-day influenza-related hospitalization. The findings from Stage 1 informed high-risk subgroups of interest for Stage 2, where we selected cohorts of influenza patients during influenza seasons from October 1, 2014 to March 1, 2019 and used 1:1 propensity score matching to patients without influenza with similar high-risk characteristics to compare influenza-attributable rates of all-cause hospital and emergency department (ED) visits during follow-up (30-day and in the index influenza season).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In Stage 1, more than 1.6 million influenza cases were identified, of which 18,509 (1.2%) had a hospitalization. Elderly age was associated with 9 times the odds of hospitalization (\u226565\u2009years vs. 5\u201317\u2009years; OR\u2009=\u20099.4, 95% CI 8.8\u201310.1) and select comorbidities were associated with 2\u20133 times the odds of hospitalization. In Stage 2, elderly influenza patients with comorbidities had 3 to 7 times higher 30-day hospitalization rates compared to matched patients without influenza, including patients with congestive heart failure (41.0% vs.7.9%), chronic obstructive pulmonary disease (34.6% vs. 6.1%), coronary artery disease (22.8% vs. 3.8%), and late-stage chronic kidney disease (44.1% vs. 13.1%; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The risk of influenza-related complications is elevated in the elderly, especially those with certain underlying comorbidities, leading to excess healthcare resource utilization. Continued efforts, beyond currently available vaccines, are needed to reduce influenza burden in high-risk populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-022-08586-y","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T09:04:28Z","timestamp":1664355868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Burden of influenza hospitalization among high-risk groups in the United States"],"prefix":"10.1186","volume":"22","author":[{"given":"Aimee M.","family":"Near","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinong","family":"Young-Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina M.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"8586_CR1","volume-title":"Disease Burden of Influenza","author":"Centers for Disease Control and Prevention","year":"2020","unstructured":"Centers for Disease Control and Prevention. Disease Burden of Influenza. 2020, 2021 [cited 2021 September 13]; Available from: https:\/\/www.cdc.gov\/flu\/about\/burden\/index.html."},{"issue":"27","key":"8586_CR2","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1016\/j.vaccine.2018.05.057","volume":"36","author":"W Putri","year":"2018","unstructured":"Putri W, et al. Economic burden of seasonal influenza in the United States. Vaccine. 2018;36(27):3960\u20136.","journal-title":"Vaccine"},{"issue":"27","key":"8586_CR3","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","volume":"25","author":"NA Molinari","year":"2007","unstructured":"Molinari NA, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27):5086\u201396.","journal-title":"Vaccine"},{"key":"8586_CR4","doi-asserted-by":"publisher","unstructured":"Ghebrehewet S, MacPherson P, Ho A. Influenza. BMJ. 2016; 355:i6258. https:\/\/doi.org\/10.1136\/bmj.i6258.","DOI":"10.1136\/bmj.i6258"},{"issue":"10","key":"8586_CR5","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/cid\/cix1060","volume":"66","author":"JI Tokars","year":"2018","unstructured":"Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018;66(10):1511\u20138.","journal-title":"Clin Infect Dis"},{"key":"8586_CR6","volume-title":"Influenza (Flu) Background and Epidemiology","author":"Centers for Disease Control and Prevention","year":"2019","unstructured":"Centers for Disease Control and Prevention. Influenza (Flu) Background and Epidemiology. 2019, 2021 [cited 2021 September 13]; Available from: https:\/\/www.cdc.gov\/flu\/professionals\/acip\/background-epidemiology.htm."},{"issue":"2","key":"8586_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6602a1","volume":"66","author":"LA Grohskopf","year":"2017","unstructured":"Grohskopf LA, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017\u201318 Influenza Season. MMWR Recomm Rep. 2017;66(2):1\u201320.","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"8586_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1017\/S0950268814001198","volume":"143","author":"KK Wong","year":"2015","unstructured":"Wong KK, et al. Estimated paediatric mortality associated with influenza virus infections, United States, 2003\u20132010. Epidemiol Infect. 2015;143(3):640\u20137.","journal-title":"Epidemiol Infect"},{"key":"8586_CR9","volume-title":"People at Higher Risk of Flu Complications","author":"Centers for Disease Control and Prevention","year":"2021","unstructured":"Centers for Disease Control and Prevention. People at Higher Risk of Flu Complications. 2021, 2021 [cited 2021 September 13]; Available from: https:\/\/www.cdc.gov\/flu\/highrisk\/index.htm."},{"key":"8586_CR10","doi-asserted-by":"publisher","first-page":"f5061","DOI":"10.1136\/bmj.f5061","volume":"347","author":"D Mertz","year":"2013","unstructured":"Mertz D, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061.","journal-title":"BMJ"},{"issue":"7","key":"8586_CR11","doi-asserted-by":"publisher","first-page":"e1001053","DOI":"10.1371\/journal.pmed.1001053","volume":"8","author":"MD Van Kerkhove","year":"2011","unstructured":"Van Kerkhove MD, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med. 2011;8(7):e1001053.","journal-title":"PLoS Med"},{"key":"8586_CR12","volume-title":"European Congress of Clinical Microbiology and Infectious Diseases","author":"A Near","year":"2020","unstructured":"Near A, Tse J, Xu YY, Connolly L, Reyes C. Incidence of medically-attended influenza and influenza-related hospitalisations by co-morbidities among a commercially insured population in the United States. In: European Congress of Clinical Microbiology and Infectious Diseases. 2020. Virtual."},{"key":"8586_CR13","volume-title":"Flu Vaccination Coverage, United States, 2019\u201320 Influenza Season","author":"Centers for Disease Control and Prevention","year":"2020","unstructured":"Centers for Disease Control and Prevention. Flu Vaccination Coverage, United States, 2019\u201320 Influenza Season. 2020, 2020 [cited 2021 September 13]; Available from: https:\/\/www.cdc.gov\/flu\/fluvaxview\/coverage-1920estimates.htm."},{"key":"8586_CR14","volume-title":"2019 Population Estimates by Age, Sex, Race and Hispanic Origin","author":"U.S. Census Bureau","year":"2021","unstructured":"U.S. Census Bureau. 2019 Population Estimates by Age, Sex, Race and Hispanic Origin. 2021 [cited 2022 July 12]; Available from: https:\/\/www.census.gov\/newsroom\/press-kits\/2020\/population-estimates-detailed.html."},{"key":"8586_CR15","volume-title":"State Population Totals and Components of Change: 2010\u20132019","author":"U.S. Census Bureau","year":"2021","unstructured":"U.S. Census Bureau. State Population Totals and Components of Change: 2010\u20132019. 2021 [cited 2022 July 12]; Available from: https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/popest\/2010s-state-total.html."},{"issue":"4","key":"8586_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s41669-020-00209-8","volume":"4","author":"JP Cohen","year":"2020","unstructured":"Cohen JP, et al. Estimation of the Incremental Cumulative Cost of HIV Compared with a Non-HIV Population. Pharmacoecon Open. 2020;4(4):687\u201396.","journal-title":"Pharmacoecon Open"},{"issue":"40","key":"8586_CR17","doi-asserted-by":"publisher","first-page":"6334","DOI":"10.1016\/j.vaccine.2020.07.023","volume":"38","author":"V Divino","year":"2020","unstructured":"Divino V, et al. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017\u201318 influenza season. Vaccine. 2020;38(40):6334\u201343.","journal-title":"Vaccine"},{"key":"8586_CR18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2474-13-158","volume":"13","author":"WA Blumentals","year":"2012","unstructured":"Blumentals WA, et al. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord. 2012;13:158.","journal-title":"BMC Musculoskelet Disord"},{"key":"8586_CR19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/s12889-015-1885-0","volume":"15","author":"B Ehlken","year":"2015","unstructured":"Ehlken B, et al. Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany--results of a database analysis from May 2010 to April 2012. BMC Public Health. 2015;15:578.","journal-title":"BMC Public Health"},{"key":"8586_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1472-6963-1-8","volume":"1","author":"DE Irwin","year":"2001","unstructured":"Irwin DE, et al. Impact of patient characteristics on the risk of influenza\/ILI-related complications. BMC Health Serv Res. 2001;1:8.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"8586_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2165\/00019053-200321040-00005","volume":"21","author":"J Loughlin","year":"2003","unstructured":"Loughlin J, et al. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics. 2003;21(4):273\u201383.","journal-title":"Pharmacoeconomics"},{"issue":"33","key":"8586_CR22","doi-asserted-by":"publisher","first-page":"e4599","DOI":"10.1097\/MD.0000000000004599","volume":"95","author":"M Rahmqvist","year":"2016","unstructured":"Rahmqvist M, Gjessing K, Faresjo T. Influenza-related healthcare visits, hospital admissions, and direct medical costs for all children aged 2 to 17 years in a defined Swedish region, monitored for 7 years. Medicine (Baltimore). 2016;95(33):e4599.","journal-title":"Medicine (Baltimore)"},{"key":"8586_CR23","doi-asserted-by":"crossref","unstructured":"Uyeki TM, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clin Infect Dis.\u00a02019;68(6):e1\u2013e47.","DOI":"10.1093\/cid\/ciy866"},{"key":"8586_CR24","volume-title":"Open Forum Infectious Diseases","author":"C Burudpakdee","year":"2019","unstructured":"Burudpakdee C, et al. 2758. Identifying Populations at High-Risk for Influenza-Related Hospitalization: A Real-World Analysis of Commercially Insured Population in the United States. In:  Open Forum Infectious Diseases; 2019."},{"key":"8586_CR25","volume-title":"HCUP Methods Series Report # 2004\u20131","author":"A Elixhauser","year":"2004","unstructured":"Elixhauser A, Steiner C, Kruzikas D. Comorbidity Software Documentation. In:  HCUP Methods Series Report # 2004\u20131: U.S. Agency for Healthcare Research and Quality; 2004."},{"key":"8586_CR26","volume-title":"People at High Risk of Developing Serious Flu\u2013Related Complications","author":"Centers for Disease Control and Prevention","year":"2018","unstructured":"Centers for Disease Control and Prevention. People at High Risk of Developing Serious Flu\u2013Related Complications. 2018 [cited 2018 November 9]; Available from: https:\/\/www.cdc.gov\/flu\/about\/disease\/high_risk.htm."},{"issue":"8 Suppl","key":"8586_CR27","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","volume":"66","author":"EA Stuart","year":"2013","unstructured":"Stuart EA, Lee BK, Leacy FP. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S84\u2013S90.e1.","journal-title":"J Clin Epidemiol"},{"key":"8586_CR28","volume-title":"Flu & People 65 Years and Older","author":"Centers for Disease Control and Prevention","year":"2021","unstructured":"Centers for Disease Control and Prevention. Flu & People 65 Years and Older. 2021, 2021 [cited 2021 September 13]; Available from: https:\/\/www.cdc.gov\/flu\/highrisk\/65over.htm."},{"key":"8586_CR29","doi-asserted-by":"crossref","unstructured":"Beigel JH, Hayden FG. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med. 2021;11(4):a038463.","DOI":"10.1101\/cshperspect.a038463"},{"key":"8586_CR30","volume-title":"Vaccine Effectiveness: How Well Do the Flu Vaccines Work?","author":"Centers for Disease Control and Prevention","year":"2021","unstructured":"Centers for Disease Control and Prevention. Vaccine Effectiveness: How Well Do the Flu Vaccines Work? 2021, 2021 [cited 2021 September 13]; Available from: https:\/\/www.cdc.gov\/flu\/vaccines-work\/vaccineeffect.htm."},{"key":"8586_CR31","volume-title":"Immunization and infectious diseases: Objectives","author":"US Department of Health and Human Services","year":"2020","unstructured":"US Department of Health and Human Services. Immunization and infectious diseases: Objectives. 2020 [cited 2021 August 3]; Available from: http:\/\/www.healthypeople.gov\/2020\/topics-objectives\/topic\/immunization-and-infectious-diseases\/objectives."},{"key":"8586_CR32","volume-title":"Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States \u2014 2019\u20132020 Influenza Season","author":"Centers for Disease Control and Prevention","year":"2021","unstructured":"Centers for Disease Control and Prevention. Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States \u2014 2019\u20132020 Influenza Season. 2021, 2021 [cited 2021 September 13]; Available from: https:\/\/www.cdc.gov\/flu\/about\/burden\/2019\u20132020.html."},{"key":"8586_CR33","volume-title":"Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States \u2014 2019\u20132020 Influenza Season","author":"CDC","year":"2021","unstructured":"CDC. Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States \u2014 2019\u20132020 Influenza Season: Centers for Disease Control and Prevention; 2021."},{"issue":"6","key":"8586_CR34","doi-asserted-by":"publisher","first-page":"e66312","DOI":"10.1371\/journal.pone.0066312","volume":"8","author":"D Kostova","year":"2013","unstructured":"Kostova D, et al. Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005\u20132011. PLoS One. 2013;8(6):e66312.","journal-title":"PLoS One"},{"issue":"1","key":"8586_CR35","doi-asserted-by":"publisher","first-page":"e0170550","DOI":"10.1371\/journal.pone.0170550","volume":"12","author":"P Schmid","year":"2017","unstructured":"Schmid P, et al. Barriers of Influenza Vaccination Intention and Behavior - A Systematic Review of Influenza Vaccine Hesitancy, 2005\u20132016. PLoS One. 2017;12(1):e0170550.","journal-title":"PLoS One"},{"issue":"1","key":"8586_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/JAC.0000000000000360","volume":"44","author":"A Coustasse","year":"2021","unstructured":"Coustasse A, Kimble C, Maxik K. COVID-19 and Vaccine Hesitancy: A Challenge the United States Must Overcome. J Ambul Care Manage. 2021;44(1):71\u20135.","journal-title":"J Ambul Care Manage"},{"issue":"42","key":"8586_CR37","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1016\/j.vaccine.2015.08.082","volume":"33","author":"A Palache","year":"2015","unstructured":"Palache A, et al. Seasonal influenza vaccine dose distribution in 195 countries (2004\u20132013): Little progress in estimated global vaccination coverage. Vaccine. 2015;33(42):5598\u2013605.","journal-title":"Vaccine"},{"key":"8586_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","volume":"16","author":"SN Crooke","year":"2019","unstructured":"Crooke SN, et al. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25.","journal-title":"Immun Ageing"},{"key":"8586_CR39","volume-title":"How CDC Estimates the Burden of Seasonal Influenza in the U.S","author":"Centers for Disease Control and Prevention","year":"2019","unstructured":"Centers for Disease Control and Prevention. How CDC Estimates the Burden of Seasonal Influenza in the U.S. 2019, 2019 [cited 2021 September 13]; Available from: https:\/\/www.cdc.gov\/flu\/about\/burden\/how-cdc-estimates.htm."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08586-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T21:03:09Z","timestamp":1664398989000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08586-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8586"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08586-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.10.21267528","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This was a retrospective database study using de-identified data compliant with the US Health Insurance Portability and Accountability Act of 1996. Therefore, ethics approval from the Institutional Review Board (IRB) was not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.H. and C.R. reports financial support from VIR Biotechnology Inc. Y.Y. reports a relationship with VIR Biotechnology Inc. that includes: funding grants. D.H. reports a relationship with Janssen Pharmaceuticals Inc. that includes: employment. D.H. reports a relationship with VIR Biotechnology Inc. that includes: equity or stocks. C.R. reports a relationship with VIR Biotechnology Inc. that includes: employment and equity or stocks. A.N. and J.T. are employees of IQVIA, which received funding from VIR Biotechnology Inc. to conduct this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1209"}}